Literature DB >> 12355428

Beta-galactoside alpha2,3-sialyltransferase-I gene expression during Th2 but not Th1 differentiation: implications for core2-glycan formation on cell surface proteins.

Nir Grabie1, Michael W Delfs, Yaw-Chyn Lim, Jason R Westrich, Francis W Luscinskas, Andrew H Lichtman.   

Abstract

Biosynthesis of core2 O-glycans on T cell surface glycoproteins is essential for their interactions with selectins expressed by activated endothelium, and may also regulate susceptibility to apoptosis. Beta-galactoside alpha2,3-sialyltransferase-I (ST3Gal-I) is a major inhibitor of core2 O-glycan formation on CD43 and CD45 in naive T cells. Here we show that ST3Gal-I mRNA is extensively expressed during Th2, but not Th1 differentiation. Consistent with this, developing Th1 cells display the non-sialylated core1 galactose (Gal1-3GalNAc-Ser/Thr) and strongly react with peanut agglutinin, while Th2 cells do not. These Th subset differences are also associated with greater expression of the high molecular glycoform of CD43 on the surface of Th1 cells compared with Th2 cells, and similar differences in surface expression of sialyl Lewis-X. We suggest that lack of ST3Gal-I expression in Th1 cells allows the formation of surface core2 O-glycans and supports their interactions with endothelial selectins.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12355428     DOI: 10.1002/1521-4141(2002010)32:10<2766::AID-IMMU2766>3.0.CO;2-0

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

Review 1.  T cells modulate glycans on CD43 and CD45 during development and activation, signal regulation, and survival.

Authors:  Mary C Clark; Linda G Baum
Journal:  Ann N Y Acad Sci       Date:  2012-01-30       Impact factor: 5.691

2.  Mucin O-glycan branching enzymes: structure, function, and gene regulation.

Authors:  Pi-Wan Cheng; Prakash Radhakrishnan
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

3.  Galectin-1 functions as a Th2 cytokine that selectively induces Th1 apoptosis and promotes Th2 function.

Authors:  Claudia C Motran; Karen M Molinder; Scot D Liu; Françoise Poirier; M Carrie Miceli
Journal:  Eur J Immunol       Date:  2008-11       Impact factor: 5.532

4.  Functional evaluation of activation-dependent alterations in the sialoglycan composition of T cells.

Authors:  Yuko Naito-Matsui; Shuhei Takada; Yoshinobu Kano; Tomonori Iyoda; Manabu Sugai; Akira Shimizu; Kayo Inaba; Lars Nitschke; Takeshi Tsubata; Shogo Oka; Yasunori Kozutsumi; Hiromu Takematsu
Journal:  J Biol Chem       Date:  2013-12-02       Impact factor: 5.157

5.  CD43 Functions as an E-Selectin Ligand for Th17 Cells In Vitro and Is Required for Rolling on the Vascular Endothelium and Th17 Cell Recruitment during Inflammation In Vivo.

Authors:  Francisco Velázquez; Anna Grodecki-Pena; Andrew Knapp; Ane M Salvador; Tania Nevers; Kevin Croce; Pilar Alcaide
Journal:  J Immunol       Date:  2015-12-23       Impact factor: 5.422

6.  Distinctive Surface Glycosylation Patterns Associated With Mouse and Human CD4+ Regulatory T Cells and Their Suppressive Function.

Authors:  Joana Cabral; Shirley A Hanley; Jared Q Gerlach; Neil O'Leary; Stephen Cunningham; Thomas Ritter; Rhodri Ceredig; Lokesh Joshi; Matthew D Griffin
Journal:  Front Immunol       Date:  2017-08-21       Impact factor: 7.561

7.  Human B Cell Differentiation Is Characterized by Progressive Remodeling of O-Linked Glycans.

Authors:  Nicholas Giovannone; Aristotelis Antonopoulos; Jennifer Liang; Jenna Geddes Sweeney; Matthew R Kudelka; Sandra L King; Gi Soo Lee; Richard D Cummings; Anne Dell; Steven R Barthel; Hans R Widlund; Stuart M Haslam; Charles J Dimitroff
Journal:  Front Immunol       Date:  2018-12-14       Impact factor: 7.561

Review 8.  Polysialic Acid in the Immune System.

Authors:  Tania M Villanueva-Cabello; Lya D Gutiérrez-Valenzuela; Roberta Salinas-Marín; Delia V López-Guerrero; Iván Martínez-Duncker
Journal:  Front Immunol       Date:  2022-02-11       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.